Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units

Aims and Method
Clozapine is an effective drug in treatment-resistant schizophrenia, but it seems to be prescribed for few patients under the age of 18 years. This study reports a survey of consultant psychiatrists working in adolescent units in the UK, looking at their use of clozapine and experience with it.

Results
Out of 83 clinicians, 59 responded (71%). More than 40% of respondents do not use clozapine, and those who do may not always be following best practice recommendations. Reasons for not using clozapine, beliefs about its effectiveness and problems encountered in its use are described.

Clinical Implications
Clozapine may not always be made available to young people with treatment-resistant schizophrenia. There is a need for more education, guidance and debate on clozapine use in child and adolescent psychiatry.

Schizophrenia can occur in children as young as 7 years old, but is very uncommon until after puberty (Jacobsen & Rapoport, 1998; Nicolson & Rapoport, 1999; National Institute for Mental Health, 2003). Among young people the clinical features, particularly likely to be preceded by premorbid abnormalities in development and social adjustment, include more commonly disorganisation and affective symptoms (Nicolson et al, 2000; Schaeffer & Ross, 2002). Reduction of environmental stress, psychoeducation (of the patient, the family and the school), psychotherapy (family work and cognitive–behavioural psychotherapy), promoting continued education, and social support are all considered important elements of treatment (Briess & Reveley, 1997). Nevertheless, pharmacotherapy remains the cornerstone of treatment, although side-effects and treatment resistance to antipsychotics are more common than in adults (Clark & Lewis, 1998; Malhotra et al, 2000; Asarnow et al, 2004).

Delay in treatment is associated with poorer results, whereas early intervention appears beneficial: the longer the duration of untreated psychosis the worse the condition becomes, with functional outcome appearing to decline sharply (Joyce et al, 2002; Harrigan et al, 2003). Early treatment thus has the potential to reduce the secondary impacts of this serious mental illness such as suicide, stigma, isolation and reduction in social status (Duggan et al, 2003; Meltzer & Baldessarini, 2003).

Clozapine is the only drug licensed for the treatment of schizophrenia in individuals as young as 16 years who are unresponsive to or intolerant of conventional medication. In the summary of product characteristics by the manufacturer (Novartis) is that they should have an electroencephalogram (EEG) prior to starting treatment and at regular intervals during the course of treatment owing to the increased incidence of absences and seizures (Frazier et al, 2003; Freedman et al, 1994; Fink, 2002).

According to the Clozaril Patient Monitoring Service, in April 2004, out of more than 21 000 patients on the register, there were just 88 patients under the age of 18 years in the UK. This is such a small number that it is possible that young people are not being offered treatment with clozapine. This would not only contravene the National Institute for Clinical Excellence guidance on atypical antipsychotics, which states that ‘in individuals with evidence of treatment resistant schizophrenia clozapine should be introduced at the earliest opportunity’ (National Institute for Clinical Excellence, 2002), but it would also deprive patients of a potentially unique and effective treatment. Some studies in fact suggest that its use might be worthwhile and beneficial in children and young people (Kumra et al, 1996; MacEwan & Morton, 1996; Turetz et al, 1997).
Thus there is accumulating evidence to advocate the early use of clozapine, although this medication has the potential to cause severe side-effects. This paper reports the results of a survey of the attitudes and prescribing practices related to clozapine in a sample of consultants in adolescent psychiatry.

Method

The study employed a cross-sectional survey design using a questionnaire developed specifically for this project (Box 1). Questionnaire items were generated following an examination of the evidence available regarding clozapine use and through discussion with colleagues. The questionnaire was piloted with two consultants in child and adolescent psychiatry working in in-patient settings. Items covered four broad areas: usage, beliefs about effectiveness, prescribing practices, and side-effects and other problems encountered.

The population sampled comprised all consultant psychiatrists working in adolescent units in the UK. Contact details were obtained from the unit directory of the Royal College of Psychiatrists. All of the 83 practitioners eligible to take part were contacted. The questionnaire was anonymous; no attempt was made to identify the respondent consultants and there was no request for information regarding individual patients. The project was submitted to and approved by the South Sheffield research ethics committee.

Results

Of the 83 consultants contacted, 59 (71%) responded, but one person returned a blank questionnaire. Of the 58 respondents who provided data, 7 (12%) reported that they did not prescribe clozapine because of a lack of suitable cases and 17 (29%) reported that they just did not use it. Reasons given are summarised in Table 1. The prescribing practices and beliefs about clozapine in the 34 (58%) respondents who reported using it are shown in Table 2.

Participants were asked about side-effects and other problems encountered when using clozapine. The most common side-effects reported were drowsiness, reported by 25 (73%) of respondents using this drug; hypersalivation, 23 (68%); hypotension, 11 (32%); constipation, 11 (32%); and others, including urinary problems, weight gain, tachycardia, diabetes and absences/seizures, reported by 7 (21%). A number of these doctors described difficulties with prescribing this drug for young people, citing poor adherence to treatment, particularly because of the risk of weight gain. Reductions in white cell count had been experienced by 18 of the 34 respondents (53%); 7 (21%) reported having to stop clozapine because of other serious problems such as myocarditis, arrhythmias, excessive sedation, untreatable hypersalivation, overdose and lack of adherence. Twenty-six (76%) found the patient monitoring service useful in managing their prescribing.

| Reason | n (%) |
|--------|-------|
| Need for intense monitoring | 10 (59) |
| Patient’s age | 10 (59) |
| Unfamiliarity with clozapine | 7 (41) |
| Side-effects | 7 (41) |
| Cost | 1 (6) |

1. Some respondents cited more than one reason.
prescribing: for example, many do not seem to routinely request EEGs before or during the course of treatment.

Acknowledgements

I thank Drs A. Livesey and S. Spence from Sheffield for the comments given during the initial part of the project. I thank Professor D. Cottrell in Leeds for his tremendous support.

Declaration of interest

None.

References

ASARNOW, J. R., TOMPSON, M. C. & McGRAFTH, E. P. (2004) Annotation: childhood-onset schizophrenia: clinical and treatment issues. Journal of Clinical Psychology and Psychiatry and Allied Disciplines, 45, 180–194.

ATKIN, K. J. & O’SULLIVAN, D. P. (1995) Clozapine patient monitoring service. Pharmacology, 235, 484.

BRIESS, D. & REVELEY, A. (1997) Teenage schizophrenia: early diagnosis and treatment. Prescriber, 8, 67–74.

BRITISH MEDICAL ASSOCIATION & ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN (2004) British National Formulary (March issue), pp. 181–182. London & Wallingford: BMJ Books & Pharmaceutical Press.

CLARK, A. F. & LEWIS, S. W. (1998) Treatment of schizophrenia in childhood and adolescence. Journal of Clinical Psychology and Psychiatry and Allied Disciplines, 39, 1071–1081.

DUGGAN, A., WARNER, J., KNAPP, M., et al (2003) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. British Journal of Psychiatry, 182, 505–508.

FINK, M. (2002) EEG changes with antipsychotic drugs. American Journal of Psychiatry, 159, 1439.

FRAZIER, J. A., COHEN, L. G., JACOBSEN, L. K., et al (2000) Clozapine in childhood-onset schizophrenia: a report of five cases. Clinical Child Psychology and Psychiatry, 5, 403–410.

FRAZIER, J. A., COHEN, L. G., JACOBSEN, L. K., et al (1996) Childhood-onset schizophrenia. Archives of General Psychiatry, 53, 1090–1097.

MacEwan, T. H. & Morton, M. J. (1996) Use of clozapine in a child with treatment-resistant schizophrenia. British Journal of Psychiatry, 168, 376–378.

MALHOTRA, S., GUPTA, N. & SINGH, G. (2000) Clozapine in childhood-onset schizophrenia: a report of five cases. Clinical Child Psychology and Psychiatry, 5, 403–410.

MELTZER, H. Y. & BALDESSARINI, R. J. (2003) Reducing the risk of suicide in schizophrenia and affective disorders. Journal of Clinical Psychiatry, 64, 1122–1129.

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (2002) Summary: Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: NICE (http://www.nice.org.uk/pdf/ 43_Antipsychotics_summary.pdf).

NATIONAL INSTITUTE FOR MENTAL HEALTH (2003) Childhood-Onset Schizophrenia: An Update from the National Institute for Mental Health. London: NIMH (http:// www.nimh.nih.gov/publicat/ schizkids.cfm).

MOULSON, R. & RAPPORT, J. L. (1999) Childhood-onset schizophrenia: rare but worth studying. Biological Psychiatry, 46, 1418–1428.
NICOLSON, R., LENANE, M., SINGARACHARLU, S., et al (2000) Premorbid speech and language impairments in childhood-onset schizophrenia: association with risk factors. American Journal of Psychiatry, 157, 794–800.

SCHAEFFER, J. L. & ROSS, R. G. (2002) Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 538–545.

TURETZ, M., MOZES, T., TOREN, P., et al (1997) An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. British Journal of Psychiatry, 170, 507–510.

Giovanni Cirulli  Specialist Registrar in Child and Adolescent Psychiatry, Craven, Harrogate and Rural District Primary Care Trust, 2 Dragon Parade, Harrogate HG1 5BY. e-mail: Gcirulli@btopenworld.com
Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units

Giovanni Cirulli
Psychiatric Bulletin 2005, 29:377-380.
Access the most recent version at DOI: 10.1192/pb.29.10.377